Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Phase 1: First in Human NCT04143802 | Published: The Lancet, 2022 (Coskun et al.) The first-in-human study of retatrutide was a single- and multiple-ascending-dose trial in patients with type 2 diabetes
They denature
Watch the virtual event below
What: GLP-1 fatigue is feeling unusually tired, flat, or foggy while using GLP-1 medicines or during dose changesoften linked to lower total intake, missed protein, and lower fluid/electrolyte balance
US$ 27.33
US$ 21.55
US$ 22.03
US$ 29.60
